There probably isn't much to say about ARDS that hasn't been said in some form within the past couple years. We've debated continually about the optimal approach to this syndrome, in the absence of much solid evidence (the only large, multi-center RCT which has been replicated in ARDS was ACURASYS – and it failed to yield reproducible results!).
This intellectual debate is being played out on the stage of a global pandemic that is increasingly causing major resource shortages. ECMO – the traditional standby for refractory ARDS – is increasingly a scarce resource. This may force the utilization of other modalities and techniques to manage refractory patients.
The IBCC chapter is located 👉 here.
- The podcast & comments are below.
Follow us on iTunes
- PulmCrit: New ARDS guidelines reveal a shambolic state of affairs - December 10, 2023
- PulmCrit wee – Loading dose pharmacokinetics for antibiotics - December 8, 2023
- PulmCrit blogitorial: Why I don't believe the AMIKINHAL trial - October 26, 2023